Abstract
Purpose
To determine the histological types of brain tumors diagnosed at the Kenyatta National Hospital, Nairobi, Kenya.
Methods
This retrospective study retrieved patient-archived records at the Kenyatta National Hospital for the period 2016–2019. The histological types of brain tumors were assessed according to age, sex, and the WHO classification for CNS tumors using the GNU PSPP version 1.6.2-g78a33 software. Results were presented in tables and figures.
Results
During the study period, brain tumors appeared to increase gradually; however, there was a decline in 2018. During the study period, 345 brain tumor records were retrieved. Data on age were missing 33 records; hence, 312 records were included for age analyses. The mean age for the pediatrics and adults was 9 (± 5 SD) and 45 (± 14 SD) years, respectively. 88 (28.2%) and 224 (71.8%) tumors were diagnosed among pediatrics and adults, respectively. Most tumors, 60 (19.2%) were reported in patients aged ≤ 10 years, followed by 55 (17.6%), 48 (15.4%), and 47 (15.1%) in patients aged 31–40, 51–60, and 41–50, years, respectively. In both pediatrics and adults, most tumors were diagnosed in females aged ≤ 10 years and 31–40 years, respectively. Overall, two peaks were observed in patients aged 5–15 years and 40–45 years. Gliomas, 43 (48.9%) and medulloblastomas, 21 (23.9%) were the most common tumors in pediatrics, whereas meningiomas, 107 (47.8%) and gliomas, 70 (31.3%) were the most common tumors in adults. Most pediatric and adult tumors were benign with 50 (56.8%) and 157 (70.1%) cases, respectively. Low-grade gliomas and medulloblastomas were the commonest benign and malignant tumors among pediatrics, with 31 (62%) and 21 (55.3%) cases, respectively. Conversely, meningiomas and high-grade gliomas were the most common benign and malignant tumors in adults, with 106 (67.5%) and 44 (65.7%) cases, respectively.
Conclusion
This study highlights the existing burden of brain tumors in Kenya and data from KNH may be representative of the national burden of BTs. This study lays a foundation for subsequent clinical and epidemiological studies and emphasizes the need to adopt existing reporting standards to help realize a complete picture of the burden of brain tumors in Kenya.
Keywords: Brain tumors, Gliomas, Medulloblastomas, Meningiomas, Kenya
Introduction
Globally, in 2020, approximately 19.3 million new cancers and 10 million deaths from cancer were reported. Of these, brain tumors (BTs) constituted approximately 308,102 (1.6%) new cases and 251,329 (2.5%) deaths [1]. The prevalence of BTs varies according to sex, age at diagnosis, geographical location, race, histological type, and genetic and environmental risk factors and may exhibit temporal incidence trends [2]. Across all World Health Organization (WHO) regions, the annual number of new cases based on pathology was 654,577 (68%) benign and 302,715 (32%) malignant BTs in 2019 [3]. The WHO African region reported 82,481 (8%) new annual cases of both benign and malignant BTs [3]. According to the GLOBOCAN report (2020), the total new cancer cases and deaths in Kenya were 42,166 and 27,092, respectively [4]. Kenya reported 686 (1.6%) benign and malignant BTs and 560 (2.1%) deaths of all new cancer cases and deaths, respectively [4]. Low reporting may explain the low incidence, prevalence, and mortality rates in some Asian and sub-Saharan African countries, which often lack registries, or the existing registries do not include BTs [2, 5].
Brain tumors exhibit a bimodal age distribution, with peaks in incidence, both in childhood ≤ 5 years and adulthood between 45 and 70 years [2, 6]. Notably, in children under 15 years, primary BTs are the most diagnosed solid tumors [7], whereas metastatic BTs are the eight most frequently isolated malignancy in adults > 40 years [8]. Pilocytic astrocytomas and embryonal tumors are common in children, whereas meningiomas, malignant gliomas, and pituitary adenomas are mainly diagnosed in adults [9, 10]. Meningiomas are the most common benign BTs and are more frequently diagnosed in women. Gliomas are the most common malignant BTs and are more frequently diagnosed in men [11, 12]. Malignant BTs are largely due to brain metastases and can be up to tenfold more common than primary tumors [13]. The increased prevalence of brain metastases is attributed to improved cancer care, and thus, cancer patients live longer with an estimated 20–40% likelihood of developing BTs [14]. Primary cancers of the lung, breast, melanoma, and kidney are most likely to metastasize to the brain. However, any primary cancer can generally metastasize to the brain [15, 16]. Primary malignant BTs also contribute significantly to malignant BTs [15]. In low- and middle-income countries, including Kenya, there are inadequate and noncomprehensive data on the burden of BTs, as evidenced by the limited existence of cancer registries, especially for BTs [2, 5, 17, 18]. A few studies based on cancer registries and hospital records have reported very few BTs in Kenya [19, 20]. However, these studies fail to reveal the burden of BTs in Kenya.
Imaging studies, primarily magnetic resonance imaging and computed tomography, are used to locate BTs [21]. The definitive diagnosis is established by histological examination and further characterization by immunohistochemistry and molecular studies where available [22]. Historically, the diagnosis and classification of BTs have been based solely on the histological presentation of the tumor using light microscopy. The WHO classification of tumors of the central nervous system is used to grade tumors into grade 1, 2, 3, and 4 [22]. The integration of molecular techniques in diagnosing BTs has enabled the molecular classification of BTs and potential improvement in diagnostic accuracy, patient management, and objective monitoring of treatment [22]. The current WHO classification integrates molecular genetics and molecular profiling of BTs with conventional techniques, such as electron microscopy, histology, and immunohistochemistry [23]. However, where molecular resources are unavailable, histological diagnosis is sufficient to diagnose BTs [22, 23]. Therefore, this study aimed to determine the histological types of brain tumors diagnosed in a national referral hospital in Nairobi, Kenya.
Methods
Study design and setting
This was a descriptive retrospective study that was conducted at the Kenyatta National Hospital (KNH) in Nairobi, Kenya. KNH is the largest referral, teaching, and research hospital in Kenya, with an 1800-bed capacity. Moreover, it is in the nation’s capital and remains the main center for neurosurgical and neurooncological care in Kenya. As a result, most patients with BTs continue to present at the hospital.
Source of data and data collection
The data in this study were obtained from brain tumor patient records at KNH. Complete records of patients with BTs in all age groups were included. Data variables included age, sex, histological diagnosis, and the WHO grade of BTs. Data were collected using Microsoft Excel 2019 (Microsoft Corp., Redmond, WA, USA). Patient records were retrieved with the assistance of a health records officer.
Data analysis
Data entry and cleaning were performed using Microsoft Excel 2019 (Microsoft Corp., Redmond, WA, USA). Statistical analysis of the BTs was performed according to patient age, sex, and histological type, and WHO grade. GNU PSPP version 1.6.2-g78a33 software was used to analyze the data and produce tables and graphs.
Ethical consideration
Ethical approval for this study was obtained from the Kenyatta National Hospital and the University of Nairobi (KNH/UoN) Ethics and Research Committee (registration number UP506/09/2020). All methods in this study adhered to the relevant guidelines and regulations. Permission to access patient records was obtained from the head of Laboratory Medicine Department and the Laboratory Manager Histopathology at KNH. The need for informed consent was waived by the KNH/UoN Nairobi Ethics and Research Committee as this was a retrospective study.
Results
Trends in brain tumors diagnosed between 2016 and 2019
87, 91, 64, and 103 brain tumor cases were reported in 2016, 2017, 2018, and 2019, respectively. Generally, the cases appeared to increase during the study period, with a significant decline in 2018 (Fig. 1).
Fig. 1.
Figure showing trends in brain tumors between 2016 and 2019
Age assessment of all brain tumors
During the study period, 345 brain tumor records were retrieved. Age data were missing for 33 records; hence, 312 records were included for age analyses. The mean age for the pediatrics (≤ 20 years) and adults was 9 (± 5 SD) and 45 (± 14 SD) years, respectively. Eighty-eight (28.2%) and 224 (71.8%) tumors were diagnosed among pediatrics and adults, respectively. Most tumors, 60 (19.2%) were reported in patients aged ≤ 10 years, followed by 55 (17.6%), 48 (15.4%), and 47 (15.1%) in patients aged 31–40, 51–60, and 41–50, years, respectively. In both pediatrics and adults, most tumors were diagnosed in females aged ≤ 10 years and 31–40 years, respectively (Table 1).
Table 1.
Distribution of brain tumors according to age and sex
| Age category | Female n (%) | Malen (%) | Total n (%) |
|---|---|---|---|
| ≤10 years | 33 (19.3) | 27 (19.1) | 60 (19.2) |
| 11–20 years | 15 (8.8) | 13 (9.2) | 28 (9) |
| 21–30 years | 19 (11.1) | 21 (14.9) | 40 (12.8) |
| 31–40 years | 32 (18.7) | 23 (16.3) | 55 (17.6) |
| 41–50 years | 29 (17) | 18 (12.8) | 47 (15.1) |
| 51–60 years | 28 (16.4) | 20 (14.2) | 48 (15.4) |
| ≤61 years | 15 (8.8) | 19 (13.5) | 34 (10.9) |
| Total | 171 (100) | 141 (100) | 312 (100) |
There was a bimodal distribution of the brain tumors with peaks at 5–15 years and 40–45 years (Fig. 2).
Fig. 2.
Histogram showing the distribution of brain tumors according to age
Assessment of brain tumors according to sex
Of 345 cases, 190 (55.1%) were diagnosed in females, while 155 (44.9%) were diagnosed among males. Cumulatively, meningiomas were the most prevalent tumors followed by gliomas, medulloblastomas, brain metastasis and pituitary adenomas with 128 (37.1%) and 118 (34.%), 26 (7.5%), 19 (5.5), and 15 (4.3), respectively. Meningiomas were most common in females, with 86 (50.6%) cases, followed by gliomas, with 48 (28.2%) cases. In males, gliomas were most common, with 59 (40.4%) cases, followed by meningiomas, with 29 (19.9%) cases (Table 2).
Table 2.
Histological distribution of brain tumors according to sex
| Tumor type | Female n (%) | Male n (%) | Total N (%) |
|---|---|---|---|
| Meningioma | 96 (50.5) | 32 (20.6) | 128 (37.1) |
| Glioma | 55 (28.9) | 63 (40.6) | 118 (34.2) |
| Medulloblastoma | 10 (5.3) | 16 (10.3) | 26 (7.5) |
| Brain metastasis | 10 (5.3) | 9 (5.8) | 19 (5.5) |
| Pituitary adenoma | 6 (3.2) | 9 (5.8) | 15 (4.3) |
| Ependymoma | 4 (2.1) | 6 (3.9) | 10 (2.9) |
| Hemangioblastoma | 1 (0.5) | 9 (5.8) | 10 (2.9) |
| Craniopharyngioma | 3 (1.6) | 5 (3.2) | 8 (2.3) |
| PNET | 1 (0.5) | 2 (1.3) | 3 (0.9) |
| Choroid plexus papilloma | 2 (1.1) | 0 (0) | 2 (0.6) |
| Hemangiopericytoma | 0 (0) | 2 (1.3) | 2 (0.6) |
| Lymphoma | 1 (0.5) | 1 (0.6) | 2 (0.6) |
| Germinoma | 0 (0) | 1 (0.6) | 1 (0.3) |
| Schwannoma | 1 (0.5) | 0 (0) | 1 (0.3) |
| Total | 190 (100) | 155 (100) | 345 (100) |
PNET: primitive neuroectodermal tumor
Assessment of pediatric brain tumors
Gliomas (43, 48.9%), followed by medulloblastomas (21, 23.9%), were the most common tumors of all pediatric tumors. Most, 50 (56.8%) pediatric tumors were benign (WHO grade 1 and 2), whereas 38 (43.2%) were malignant (WHO grade 3 and 4). Low-grade gliomas and ependymomas were the most common benign tumors, with 31 (62%) and 7 (14%) cases, respectively. Medulloblastomas and high-grade gliomas were the most common malignant tumors, with 21 (55.3%) and 10 (31.6%) cases, respectively (Table 3).
Table 3.
Distribution of pediatric brain tumors according to the WHO Classification of CNS tumors
| Diagnosis | WHO Grade 1 n (%) | WHO Grade 2 n (%) | WHO Grade 3 n (%) | WHO Grade 4 n (%) | Total N (%) |
|---|---|---|---|---|---|
| Glioma | 28 (68.3) | 3 (33.3) | 3 (75) | 9 (26.5) | 43 (48.9) |
| Medulloblastoma | 0 (0) | 0 (0) | 0 (0) | 21 (61.8) | 21 (23.9) |
| Ependymoma | 2 (4.9) | 5 (55.6) | 1 (25) | 0 (0) | 8 (9.1) |
| Craniopharyngioma | 4 (9.8) | 0 (0) | 0 (0) | 0 (0) | 4 (4.5) |
| Meningioma | 2 (4.9) | 1 (11.1) | 0 (0) | 0 (0) | 3 (3.4) |
| PNET | 0 (0) | 0 (0) | 0 (0) | 3 (8.8) | 3 (3.4) |
| Choroid plexus papilloma | 2 (4.9) | 0 (0) | 0 (0) | 0 (0) | 2 (2.3) |
| Germinoma | 0 (0) | 0 (0) | 0 (0) | 1 (2.9) | 1 (1.1) |
| Hemangioblastoma | 1 (2.4) | 0 (0) | 0 (0) | 0 (0) | 1 (1.1) |
| Pituitary adenoma | 1 (2.4) | 0 (0) | 0 (0) | 0 (0) | 1 (1.1) |
| Schwannoma | 1 (2.4) | 0 (0) | 0 (0) | 0 (0) | 1 (1.1) |
| Total | 41 (100) | 9 (100) | 4 (100) | 34 (100) | 88 (100) |
PNET: primitive neuroectodermal tumor
Distribution of adult brain tumors
Meningiomas, 107 (47.8%) were the most common tumors of all adult BTs, followed by gliomas, brain metastasis, and pituitary adenomas with 70 (31.3%), 17 (7.6%), and 11 (4.9%), respectively. Most 157 (70.1%) adult tumors were benign, whereas 67 (29.9%) were malignant. Meningiomas and low-grade gliomas were the most common benign tumors, with 106 (67.5%) and 26 (16.6%) cases, respectively. High-grade gliomas and brain metastases were the most common malignant tumors, with 44 (65.7%) and 17 (25.4%) cases, respectively (Table 4).
Table 4.
Distribution of adult brain tumors according to the WHO Classification of CNS tumors
| Diagnosis | WHO Grade 1 n (%) | WHO Grade 2 n (%) | WHO Grade 3 n (%) | WHO Grade 4 n (%) | Total N (%) |
|---|---|---|---|---|---|
| Meningioma | 97 (75.8) | 9 (31) | 1 (33.3) | 0 (0) | 107 (47.8) |
| Glioma | 7 (5.5) | 19 (65.5) | 1 (33.3) | 43 (67.2) | 70 (31.3) |
| Brain metastasis | 0 (0) | 0 (0) | 0 (0) | 17 (26.6) | 17 (7.6) |
| Pituitary adenoma | 11 (8.6) | 0 (0) | 0 (0) | 0 (0) | 11 (4.9) |
| Hemangioblastoma | 8 (6.3) | 0 (0) | 0 (0) | 0 (0) | 8 (3.6) |
| Craniopharyngioma | 4 (3.1) | 0 (0) | 0 (0) | 0 (0) | 4 (1.8) |
| Medulloblastoma | 0 (0) | 0 (0) | 0 (0) | 3 (4.7) | 3 (1.3) |
| Ependymoma | 0 (0) | 1 (3.4) | 1 (33.3) | 0 (0) | 2 (0.9) |
| Hemangiopericytoma | 1 (0.8) | 0 (0) | 0 (0) | 0 (0) | 1 (0.4) |
| Lymphoma | 0 (0) | 0 (0) | 0 (0) | 1 (1.6) | 1 (0.4) |
| Total | 128 (100) | 29 (100) | 3 (100) | 64 (100) | 224 (100) |
Distribution of gliomas according to age and sex
Of all tumors assessed by age, 113 were gliomas; of these, 54 (47.8%) were diagnosed in female patients, whereas 59 (52.2%) were diagnosed in males. Among females, most cases, 15 (27.8%) cases were reported in patients aged ≤ 10 years, followed by those between 11 and 20 years, with 10 (8.8%) cases. Among males, most, 11 (18.6%) cases were reported in patients aged ≤ 10 years, followed by those between 31 and 40 and 51–60 years with 10 (16.9%) each (Table 5).
Table 5.
Distribution of gliomas according to age and sex
| Age category | Female n (%) | Male n (%) | Total n (%) |
|---|---|---|---|
| ≤10 years | 15 (27.8) | 11 (18.6) | 26 (23) |
| 11–20 years | 10 (8.8) | 7 (11.9) | 17 (15) |
| 21–30 years | 7 (13) | 5 (8.5) | 12 (10.6) |
| 31–40 years | 7 (13) | 10 (16.9) | 17 (15) |
| 41–50 years | 4 (7.4) | 9 (15.3) | 13 (11.5) |
| 51–60 years | 8 (14.8) | 10 (16.9) | 18 (15.9) |
| ≤61 years | 3 (5.6) | 7 (11.9) | 10 (8.8) |
| Total | 54 (100) | 59 (100) | 113 (100) |
Distribution of meningiomas according to age and sex
Of all tumors assessed by age, 110 were meningiomas. 85 (77.3%) were diagnosed in female patients, whereas 25 (22.7%) were diagnosed in male patients. Among females, most, 25 (29.4%) cases were reported in patients aged between 31 and 40 years, followed by those between 41 and 50 years, with 21 (24.7%) cases. Among males, 7 (28%) cases were reported in patients aged 51–60 years, followed by those between 31 and 40 years with 6 (24%) cases (Table 6).
Table 6.
Distribution of meningiomas according to age and sex
| Age category | Female vn (%) | Male n (%) | Total n (%) |
|---|---|---|---|
| ≤10 years | 2 (2.4) | 0 (0) | 2 (1.8) |
| 11–20 years | 1 (1.2) | 0 (0) | 1 (0.9) |
| 21–30 years | 10 (11.8) | 4 (16) | 14 (12.7) |
| 31–40 years | 25 (29.4) | 6 (24) | 31 (28.2) |
| 41–50 years | 21 (24.7) | 3 (12) | 24 (21.8) |
| 51–60 years | 17 (20) | 7 (28) | 24 (21.8) |
| ≤61 years | 9 (10.6) | 5 (20) | 14 (12.7) |
| Total | 85 (100) | 25 (100) | 110 (100) |
Discussion
In this study, brain tumor cases showed an increasing trend over the years. The highest number of cases was reported in 2019; whereas a decline was observed in 2018. The low cases prior to 2019 may be attributed to various challenges at the institutional and health system challenges, including inadequate ICU beds, fewer surgery days due to less theaters available for neurosurgery, prioritization of other surgical emergencies over elective neurosurgeries, and sporadic nationwide health service disruption due to industrial actions [24]. Subsequently, dedicated neurosurgical theaters were set up with daily neurosurgery electives, which may explain the higher cases in 2019. However, these cases may not reflect the true burden of BTs in Kenya considering KNH remains the main neurosurgical and neurooncological care center. Patient factors, such as healthcare seeking behaviors, health system challenges, including service delivery, health workforce, health system financing, and neurosurgical and neurooncological care are largely overlooked in resource-limited settings, including Kenya [25]. This may impair health care and service delivery for brain tumors. There is also an underinvestment in healthcare infrastructure and brain tumor research in developing countries compared to developed countries [26]. There is acute shortage of comprehensive neurooncological care, including radiologists, neurooncologists, and neurosurgeons with dismal ratio of 1 neurosurgeon for 2.4 million people in East Africa, which Kenya is part of [27]. All these challenges may explain the persistently low incidence rates reported in the African region [1, 28].
In this study, the mean age for the pediatrics (≤ 20 years) and adults was 9 (± 5 SD) and 45 (± 14 SD) years, respectively. Most tumors, 71.8% tumors were diagnosed among adults. There was a bimodal distribution of the BTs with peaks at 5–15 years and 40–45 years. Most tumors, 60 (19.2%) were reported in patients aged ≤ 10 years, followed by 55 (17.6%), 48 (15.4%), and 47 (15.1%) in patients aged 31–40, 51–60, and 41–50, years, respectively. In both pediatrics and adults, most tumors were diagnosed in females aged ≤ 10 years and 31–40 years, respectively. This study’s mean age for pediatric BTs was relatively same to the current SEER report (United States), which reported a mean age of 8 years [29]. However, the mean age varies significantly according to the specific childhood brain tumors (CBTs) [30]. This study’s mean for adult BTs is relatively similar to another study that was conducted at the same facility in 2014 that reported a mean of 40.63 ± 15.36 years [31]. Generally, the distribution of BTs according to age was relatively similar to the local study cited above [31] and with the CBTRUS findings [32]. In this study, two peaks were observed in both childhood and adulthood, like other studies [2, 6]. The bimodal incidence of BTs is attributed to the likelihood of certain BTs occurring at a certain age due to the associated biological, genetic, and environmental risk factors [2]. Childhood tumors, such as embryonal tumors and astrocytomas, are more common in children and may have genetic predispositions [6, 8, 30]. On the other hand, malignant gliomas, meningiomas, and pituitary adenomas are common in adults [6]. Adult BTs are also associated with the relatively long duration of exposure needed for neoplastic transformation [2, 8]. Biological factors, such as hormones are attributed to high adult glioma and meningioma cases [8]. In this study, BTs diagnosed in males were 46.2% versus 53.8% in females; thus, the overall male-to-female (M:F) ratio was 1:1.6. This compared unfavorably with other African studies that reported an M:F of 1:1 [33, 34]. This could be attributed to the relatively high frequency of meningiomas diagnosed in females in this study. Gliomas were most diagnosed in males, whereas meningiomas were the most diagnosed brain tumor type in females. Gliomas had M:F ratios of 1:1.1, whereas meningiomas had a M:F ratio of 1:3.4. These findings are consistent with local and international studies [31, 35].
Gliomas and medulloblastomas were the most common pediatric tumors in this study. In addition to gliomas and medulloblastomas, other studies have reported craniopharyngiomas and ependymomas among the most frequent pediatric tumors [6]. Most pediatric tumors in this study were benign, like other studies [36]. In this study, gliomas were the most common benign pediatric BTs, whereas medulloblastomas were the most malignant brain pediatric tumors. Low-grade gliomas are the most common childhood tumors, and rarely become malignant [37]. In this study, medulloblastomas were the second most frequent of all pediatric tumors, but the most common malignant childhood BTs and were most frequently diagnosed in males, like a current review on pediatric tumors studies [30]. Medulloblastomas are the commonest component of the heterogenous group of malignant tumors known as CNS embryonal tumors [38]. CNS embryonal tumors were previously categorized as primitive neuroectodermal tumors (PNETs); however, molecular characterization necessitated the reclassification [30]. Ependymomas were the third most common tumors at 8% of all pediatric tumors in this study. This is similar to the generally reported frequency of approximately 5–10% [30]. Some of the risk factors associated with pediatric tumors include genetic factors, exposure to ionizing radiation (IR), non-chromosomal structural birth defects, high socioeconomic position, and high birth weight [8, 39]. Genetic predisposition is a known risk factor in the occurrence of pediatric ependymomas, medulloblastomas and gliomas [8, 30]. However, low-grade gliomas with isocitrate dehydrogenase 1 gene (IDH1) and IDH2 mutations, which transform to malignancy are rarer in pediatrics [40]. Longer telomere length and European ancestry are associated with increased risk for ependymomas [6]. However, genetic association studies in CBTs have not been conducted in other tumors; hence, the contribution of genetic factors is unknown in these tumors [6].
Moderate to high radiation doses are known causes of brain tumors, including CBTs [8, 39]. However, the risk of developing brain cancer from low-dose diagnostic or therapeutic radiation is debatable. The carcinogenic effects of IR are heightened in children, particularly in younger children [8]. Postnatal exposure to computed tomography was associated with increased risk for BTs [39]. Childhood exposure to therapeutic radiation for leukemia is also associated with development of BTs in adulthood [8]. Reverse causation may limit these findings as pediatrics with preexisting cancer or at a higher risk for cancer are likely to undergo computed tomography of the head [8]. During pregnancy, exposure of the mother to diagnostic radiation is also thought to increase brain cancer risk [8]. The tumors that may be induced by IR include gliomas and meningiomas [41]. Generally, non-chromosomal structural birth defects are known risk factor for CBTs with more preponderance in children aged ≤ 5 years with cancer [8]. CNS anomalies have a higher risk of CBTs. Birth weight > 4000 g is also associated with higher risk of pediatric embryonal tumors and astrocytomas [6]. However, other studies reported no associations between birth weight and CBTs [42]. There is limited evidence on the contribution of these risk factors to CBTs from low-resource settings, particularly Africa.
Overall, most adult BTs cases in this study were reported in patients aged 40–60 years. High cases were reported in female patients between 31 and 60 years in this study. Meningiomas and gliomas accounted for most of the adult BTs, with a cumulative prevalence of 79.1%. This is like other studies, both locally [31, 43] and globally [32, 33, 44]. Most adult tumors were benign, with meningiomas being the most frequent. Meningiomas mostly occur in patients in their fourth and fifth decades of life, with more female cases than males [45]. High-grade gliomas were the most frequent malignant adult tumors, followed by brain metastases. High-grade gliomas were most reported in males. In this study, metastatic tumors to the brain were the fourth most frequently reported of all tumors, with all cases in adults. This is consistent with other studies [31, 33, 46]. The increased prevalence of brain metastases is attributed to improved cancer care, and thus, cancer patients live longer, with an estimated 20–40% likelihood of developing BTs [14]. Increased access to imaging may also explain the increasing diagnosis of brain metastasis among cancer patients. The risk factors associated with adult BTs include genetic mutations, ancestry, increased leucocyte length, human leucocyte antigen (HLA) haplotypes, hormonal factors, environmental exposures, and higher socioeconomic status [6, 47]. On the contrary, some factors such as use of aspirin, statins, and history of respiratory allergies decrease the risk of adult BTs, particularly gliomas [8, 48]. Most risk association studies have been conducted in high-grade gliomas since they are the most frequent malignant BTs. Most tumors, particularly gliomas do not have a family history of glioma; however, approximately 5% are familial [8]. Studies on genetic polymorphisms in gliomas and meningiomas, pituitary adenomas, and primary CNS lymphoma have found various single nucleotide polymorphisms associated with these BTs, particularly in the European and East Asian populations [6, 49]. Increased leukocyte telomere length has been implicated in meningiomas and gliomas [50, 51]. Neurofibromatosis type 2 (NF2) mutation is also associated with meningiomas [45]. However, genetic studies are limited in Africa, including Kenya.
High-dose IR is one of the environmental exposure factors that has been widely evaluated in adult BTs and has been implicated in gliomas and meningiomas [6]. However, this may not account for the high burden of adult BTs. Studies on other environmental exposures, including radiofrequency fields emitted by cellular phones, extremely low frequency (ELF) magnetic fields, electromagnetic fields (EMF) from power lines, and other non-radiation exposures have reported conflicting results or no associations with adult BTs [52, 53]. The contribution of these environmental exposure in Kenya is unknown. Higher socioeconomic position (SEP) has been linked to higher risk for adult BTs, particularly gliomas [54, 55]. This may be due to diagnostic bias where underreporting may occur in patients with lower SEP. Another explanation is that immune exposures, particularly allergy and infections and health-seeking behavior may be influenced by SEP [6, 8]. This may explain the varied burden of BTs between higher SEP and lower SEP settings, such as Kenya. Sex hormones are hypothesized to play role in the gender-associated prevalence in meningiomas and gliomas. Estrogen and progesterone are attributed to the high frequency of meningiomas in women [47, 56]. On the other hand, testosterone is implicated in the high glioma prevalence in males [57]. Studies on the association of estrogen and progesterone and meningiomas in premenopausal and perimenopausal women have reported conflicting results [58]. A population-based case–control study reported a marginal association between meningioma and exogenous hormone exposure from oral contraceptives and hormone replacement therapy. However, other studies found no association between meningioma and hormonal exposures [59, 60]. Other studies have reported protective role of endogenous hormones against meningiomas in premenopausal women [61]. Glioblastomas, which comprise high-grade gliomas are associated with testosterone, whereas progesterone and estradiol are thought to protect against glioblastomas [57]. Most associations studies between risk factors and brain tumors have been conducted in developed countries. Further research is needed, more so in low-resource settings to establish the association of risk factors to the existing pediatric and adult brain tumors.
Study limitations
This study was dependent on the completeness of the recorded data. There was a lack of data on some variables, including tumor location, ancestry/ethnicity, and race. In addition, the lack of immunohistochemical and molecular classification of brain tumors limited the comparison of these findings to international studies.
Conclusion
This study highlights the existing burden of brain tumors in Kenya. Data from KNH may be representative of the national burden of brain tumors. This study lays a foundation for subsequent clinical and epidemiological studies and the need to adopt existing reporting standards to help realize a complete picture of the burden of brain tumors in Kenya.
Recommendations
This study recommends adherence to reporting recommendations to diagnose brain tumors. Building capacity to enable performance of the recommended tests, including immunohistochemistry and molecular studies, will help improve reporting and allow comparison to global studies.
Acknowledgements
The authors wish to thank Dr. Dennis Inyangala and Mr. Washington Otieno for reviewing this manuscript and Ms. Veronica Kimilu for her assistance with data retrieval.
Author contributions
SRG and PMO contributed to the conception and design of the study. Material preparation and data collection were performed by SRG. SRG wrote the first draft. PMO reviewed the first draft. PMM performed data reanalysis and visualization and edited the revised manuscript. All authors commented on previous manuscript versions and approved the final revised manuscript.
Funding
No funds, grants, or other support was received.
Data Availability
All data generated or analyzed during this study are included in this published article.
Declarations
Ethics approval and consent to participate
Ethical approval for this study was obtained from the Kenyatta National Hospital and the University of Nairobi (KNH/UoN) Ethics and Research Committee (registration number UP506/09/2020). All methods in this study adhered to the relevant guidelines and regulations. Permission to access patient records was obtained from the head of Laboratory Medicine Department and the Laboratory Manager Histopathology at KNH. The need for informed consent was waived by the KNH/UoN Nairobi Ethics and Research Committee as this was a retrospective study.
Consent for publication
Not applicable.
Competing interests
The authors declare no competing interests.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660. [DOI] [PubMed] [Google Scholar]
- 2.Stewart B. 2014. Wild International Agency for Research on Cancer. In: WHO CP (Ed). World Cancer Report. International Agency for Research on Cancer: Lyon.
- 3.Bell JS, Koffie RM, Rattani A, Dewan MC, Baticulon RE, Qureshi MM, et al. Global incidence of brain and spinal tumors by geographic region and income level based on cancer registry data. J Clin Neurosci. 2019;66:121–127. doi: 10.1016/j.jocn.2019.05.003. [DOI] [PubMed] [Google Scholar]
- 4.World Health Organization. 2020. Kenya Source: Globocan 2020.
- 5.Uwishema O, Frederiksen KS, Badri R, Pradhan AU, Shariff S, Adanur I, et al. Epidemiology and etiology of brain cancer in Africa: A systematic review. Brain Behav. 2023;13(9):e3112. doi: 10.1002/brb3.3112. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Ostrom QT, Francis SS, Barnholtz-Sloan JS. Epidemiology of brain and other CNS tumors current neurology and neuroscience Reports. Berlin: Springer; 2021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Hazmiri FE, Boukis F, Benali SA, El Ganouni NCI, Rais H. Brain tumors in children: about 136 cases. Pan African Med J. 2018;30:1–8. doi: 10.11604/pamj.2018.30.291.13208. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Ostrom QT, Fahmideh MA, Cote DJ, Muskens IS, Schraw JM, Scheurer ME, et al. Risk factors for childhood and adult primary brain tumors. Neuro Oncol. 2019;21(11):1357–1375. doi: 10.1093/neuonc/noz123. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.McNeill KA. Epidemiology of brain tumors. Neurol Clin. 2016;34(981):98. doi: 10.1016/j.ncl.2016.06.014. [DOI] [PubMed] [Google Scholar]
- 10.Jemal A, Torre L, Street W, Bray F. The cancer atlas. Am Cancer Soc. 2019;1–69.
- 11.Živković N, Mihailović G, Marković M, Berisavac I, Spaić M. Epidemiological features of brain tumors. Srp Arh Celok Lek. 2014;141(11–12):823–829. doi: 10.2298/sarh1312823z. [DOI] [PubMed] [Google Scholar]
- 12.Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro Oncol. 2019;21:V1–100. doi: 10.1093/neuonc/noz150. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Ahmad A, Khan P, Rehman AU, Batra SK, Nasser MW. Immunotherapy: an emerging modality to checkmate brain metastasis. Mol Cancer. 2023 doi: 10.1186/s12943-023-01818-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Bertolini F, Spallanzani A, Fontana A, Depenni R, Luppi G. Brain metastases: an overview. CNS Oncol. 2015;4(1):37–46. doi: 10.2217/cns.14.51. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Cagney DN, Martin AM, Catalano PJ, Redig AJ, Lin NU, Lee EQ, et al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017;19(11):1511–1521. doi: 10.1093/neuonc/nox077. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Berghoff AS, Schur S, Füreder LM, Gatterbauer B, Dieckmann K, Widhalm G, et al. Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers. ESMO Open. 2016;1:24. doi: 10.1136/esmoopen-2015-000024. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.MbiFeh MKN, Lyon KA, Brahmaroutu AV, Tadipatri R, Fonkem E. The need for a central brain tumor registry in Africa: a review of central nervous system tumors in Africa from 1960 to 2017. Neurooncol Pract. 2021;8(3):337–344. doi: 10.1093/nop/npaa086. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Kanmounye US, Karekezi C, Nyalundja AD, Awad AK, Laeke T, Balogun JA. Adult brain tumors in Sub-Saharan Africa: a scoping review. Neuro Oncol. 2022;24(10):1799–1806. doi: 10.1093/neuonc/noac098. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Kamita M, Mweni S, Nzioka A, Figueroa JD, Makokha F. Analysis of cancer diagnoses from 2015–2019 within Machakos County, Kenya, support establishment of Cancer Centre in 2019 likely changing referral patterns. Wellcome Open Res. 2020;16(5):290. doi: 10.12688/wellcomeopenres.16340.1. [DOI] [Google Scholar]
- 20.Kamita M, Bird P, Akinyi B, Kamau RW, Carter R, Muma S, et al. Cancer referrals at African Inland Church Kijabe Hospital, Kiambu County (2014–2020) and the impact of COVID-19. Int Health. 2023;15(5):547–556. doi: 10.1093/inthealth/ihad007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Keogh BP, Henson JW. Clinical manifestations and diagnostic imaging of brain tumors. Hematol Oncol Clin North Am. 2012;26(4):733–755. doi: 10.1016/j.hoc.2012.05.002. [DOI] [PubMed] [Google Scholar]
- 22.Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–820. doi: 10.1007/s00401-016-1545-1. [DOI] [PubMed] [Google Scholar]
- 23.Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–1251. doi: 10.1093/neuonc/noab106. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Ombuor R. New Strike Hobbles Kenya’s Largest Public Referral Hospital. 2018. https://www.voanews.com/a/bew-strike-hobbles-kenyas-largest-public-referral-hospital/4286037.html. Accessed 22 Oct 2023.
- 25.Ngulde SI, Fezeu F, Ramesh A, Moosa S, Purow B, Lopez B, et al. Improving brain tumor research in resource-limited countries: a review of the literature focusing on West Africa. Cureus. 2015 doi: 10.7759/cureus.372. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Uwishema O, Frederiksen KS, Badri R, Pradhan AU, Shariff S, Adanur I, et al. Epidemiology and etiology of brain cancer in Africa: a systematic review. Brain Behav. 2023;13(9):e3112. doi: 10.1002/brb3.3112. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Aderinto N, AbdulBasitOpeyemi M, Opanike J, Afolayan O, Sakaiwa N. Navigating the challenges of neuro-oncology in Africa: addressing diagnostic and treatment barriers in the region: a correspondence. Int J Surg Global Health. 2023;6(3):e136–e136. doi: 10.1097/GH9.0000000000000136. [DOI] [Google Scholar]
- 28.Patel AP, Fisher JL, Nichols E, Abd-Allah F, Abdela J, Abdelalim A, et al. Global, regional, and national burden of brain and other CNS cancer, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(4):376–393. doi: 10.1016/S1474-4422(18)30468-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.National Cancer Institute—Surveillance Epidemiology and End Results Program. Childhood Brain and Other Nervous System Cancer—Cancer Stat Facts. 2023. https://seer.cancer.gov/statfacts/html/childbrain.html. Accessed 30 Nov 2023.
- 30.Cohen AR. Brain tumors in children. New England J Med. 2022;386(20):1922–31. doi: 10.1056/NEJMra2116344. [DOI] [PubMed] [Google Scholar]
- 31.Muriithi SW. Pattern of Brain Tumors in Kenyatta National Hospital: a 3-Year Cross-sectional study. 2014. (Uon 2001): 1–62. http://erepository.uonbi.ac.ke/bitstream/handle/11295/95093/MMed_Solomon%0AWahome%0AMuriithi_20may2015%0A%281.pdf?sequence=3&isAllowed=y.
- 32.Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017. Neuro Oncol. 2020;22:1–96. doi: 10.1093/neuonc/noaa200. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Jibrin P, Ibebuike K, Ado-Wanka AN. Histo-pathological pattern of intracranial tumours in the national hospital. Abuja Afr Health Sci. 2018;18(2):281–286. doi: 10.4314/ahs.v18i2.12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Soyemi SS, Oyewole OO. Spectrum of intracranial tumours in a tertiary health care facility: our findings. Pan Afr Med J. 2015;20:1–5. doi: 10.11604/pamj.2015.20.24.4935. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Mwang’ombe NJM, Ombachi RB. Brain tumours at the Kenyatta National Hospital Nairobi. East Afr Med J. 2000;77(8):444–7. [PubMed] [Google Scholar]
- 36.Liu Z-M, Liao C-Y, Zhang H, Han Z, Wang J-M, Ma Z-Y, et al. Epidemiological characteristics of central nervous system tumors in children: a 5-year review of 3180 cases from Beijing Tiantan Hospital. Chin Neurosurg J. 2022 doi: 10.1186/s41016-022-00279-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Sturm D, Pfister SM, Jones DTW. Pediatric gliomas: current concepts on diagnosis, biology, and clinical management. J Clin Oncol. 2017;35(21):2370–2377. doi: 10.1200/JCO.2017.73.0242. [DOI] [PubMed] [Google Scholar]
- 38.Orr BA. Pathology, diagnostics, and classification of medulloblastoma. Brain Pathol. 2020;30(3):664–678. doi: 10.1111/bpa.12837. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Abalo KD, Rage E, Leuraud K, Richardson DB, Le Pointe HD, Laurier D, et al. Early life ionizing radiation exposure and cancer risks: systematic review and meta-analysis. Pediatr Radiol. 2021;51(1):45–56. doi: 10.1007/s00247-020-04803-0. [DOI] [PubMed] [Google Scholar]
- 40.Collins KL, Pollack IF. Pediatric Low-Grade Gliomas. Cancers (Basel) 2020 doi: 10.3390/cancers12051152. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Braganza MZ, Kitahara CM, Berrington De González A, Inskip PD, Johnson KJ, Rajaraman P. Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review. Neuro Oncol. 2012;14(11):1316–24. doi: 10.1093/neuonc/nos208. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Bailey HD, Rios P, Lacour B, Guerrini-Rousseau L, Bertozzi AI, Leblond P, et al. Factors related to pregnancy and birth and the risk of childhood brain tumours: the ESTELLE and ESCALE studies (SFCE, France) Int J Cancer. 2017;140(8):1757–1769. doi: 10.1002/ijc.30597. [DOI] [PubMed] [Google Scholar]
- 43.Muddegowda PH, Lingegowda JB, Kurpad RR, Srinivasan S, Manjunatha HK. Prevalence of primary CNS tumors in a diagnostic setup in Nairobi, Kenya. Indian J Pathol Oncol. 2018;5(4):631–5. doi: 10.18231/2394-6792.2018.0120. [DOI] [Google Scholar]
- 44.Ibebuike K, Ouma J, Gopal R. Meningiomas among intracranial neoplasms in Johannesburg, South Africa: prevalence, clinical observations and review of the literature. Afr Health Sci. 2013;13(1):118–121. doi: 10.4314/ahs.v13i1.16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Ruttledge MH, Sarrazin J, Rangaratnam S, Phelan CM, Twist E, Merel P, et al. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet. 1994;6(2):180–184. doi: 10.1038/ng0294-180. [DOI] [PubMed] [Google Scholar]
- 46.Hanif F, Muzaffar K, Perveen K, Malhi SM, Simjee SU. Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pac J Cancer Prev. 2017;18(1):3–9. doi: 10.22034/APJCP.2017.18.1.3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Custer B, Longstreth JT, Phillips LE, Koepsell TD, Van Belle G. Hormonal exposures and the risk of intracranial meningioma in women: a population-based case-control study. BMC Cancer. 2006;7:6. doi: 10.1186/1471-2407-6-152. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Amirian ES, Zhou R, Wrensch MR, Olson SH, Scheurer ME, Il’Yasova D, et al. Approaching a scientific consensus on the association between allergies and Glioma risk: a report from the Glioma international case-control study. Cancer Epidemiol Biomarkers Prev. 2016;25(2):282–90. doi: 10.1158/1055-9965.EPI-15-0847. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Melin BS, Barnholtz-Sloan JS, Wrensch MR, Johansen C, Il’Yasova D, Kinnersley B, et al. Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. Nat Genet. 2017;49(5):789–94. doi: 10.1038/ng.3823. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Walsh KM, Codd V, Rice T, Nelson CP, Smirnov IV, McCoy LS, et al. Longer genotypically-estimated leukocyte telomere length is associated with increased adult glioma risk. Oncotarget. 2015;6(40):42468–42477. doi: 10.18632/oncotarget.6468. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Muskens IS, Hansen HM, Smirnov IV, Molinaro AM, Bondy ML, Schildkraut JM, et al. Longer genotypically-estimated leukocyte telomere length is associated with increased meningioma risk. J Neurooncol. 2019;142(3):479–487. doi: 10.1007/s11060-019-03119-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Carles C, Esquirol Y, Turuban M, Piel C, Migault L, Pouchieu C, et al. Residential proximity to power lines and risk of brain tumor in the general population. Environ Res. 2020;1:185. doi: 10.1016/j.envres.2020.109473. [DOI] [PubMed] [Google Scholar]
- 53.Turner MC, Benke G, Bowman JD, Figuerola J, Fleming S, Hours M, et al. Occupational exposure to extremely low-frequency magnetic fields and brain tumor risks in the INTEROCC study. Cancer Epidemiol Biomarkers Prev. 2014;23(9):1863–1872. doi: 10.1158/1055-9965.EPI-14-0102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Porter AB, Lachance DH, Johnson DR. Socioeconomic status and glioblastoma risk: a population-based analysis. Cancer Causes Control. 2015;26(2):179–185. doi: 10.1007/s10552-014-0496-x. [DOI] [PubMed] [Google Scholar]
- 55.Cote DJ, Ostrom QT, Gittleman H, Duncan KR, CreveCoeur TS, Kruchko C, et al. Glioma incidence and survival variations by county-level socioeconomic measures. Cancer. 2019;125(19):3390–3400. doi: 10.1002/cncr.32328. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Anic GM, Madden MH, Nabors LB, Olson JJ, Larocca RV, Thompson ZJ, et al. Reproductive factors and risk of primary brain tumors in women. J Neurooncol. 2014;118(2):297–304. doi: 10.1007/s11060-014-1427-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Bello-Alvarez C, Camacho-Arroyo I. Impact of sex in the prevalence and progression of glioblastomas: the role of gonadal steroid hormones. Biol Sex Differ. 2021;12(1):1–13. doi: 10.1186/s13293-021-00372-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Anic GM, Madden MH, Nabors LB, Olson JJ, Larocca RV, Thompson ZJ, et al. Reproductive factors and risk of primary brain tumors in women. J Neurooncol. 2014;118(2):297–304. doi: 10.1007/s11060-014-1427-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Korhonen K, Raitanen J, Isola J, Haapasalo H, Salminen T, Auvinen A. Exogenous sex hormone use and risk of meningioma: a population-based case-control study in Finland. Cancer Causes Control. 2010;21(12):2149–2156. doi: 10.1007/s10552-010-9634-2. [DOI] [PubMed] [Google Scholar]
- 60.Hage M, Plesa O, Lemaire I, Sanson MLR. Estrogen and progesterone therapy and meningiomas. Endocrinology. 2022 doi: 10.1210/endocr/bqab259. [DOI] [PubMed] [Google Scholar]
- 61.Lee E, Grutsch J, Persky V, Glick R, Mendes J, Davis F. Association of meningioma with reproductive factors. Int J Cancer. 2006;119(5):1152–1157. doi: 10.1002/ijc.21950. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
All data generated or analyzed during this study are included in this published article.